Naloxone is a medication that rapidly reverses an opioid overdose by blocking the effects of opioids in the brain. It works within minutes, restoring normal breathing in someone whose body is shutting down from drugs like heroin, fentanyl, or prescription painkillers. Since 2023, a nasal spray version (sold as Narcan) has been available over the counter in the United States, meaning anyone can buy it without a prescription at pharmacies, convenience stores, and grocery stores.
How Naloxone Works in the Body
Opioids cause overdose deaths primarily by slowing breathing to a dangerous level. They do this by binding to receptors in the brain that control respiration. Naloxone is a competitive antagonist, which means it races to those same receptors and knocks the opioid molecules off. It has an especially strong grip on the main opioid receptor responsible for pain relief and respiratory depression, so it can displace even powerful synthetic opioids like fentanyl.
The key word is “competitive.” Naloxone doesn’t destroy the opioid or flush it from the body. It simply outcompetes it for space on the receptor. Once naloxone occupies the receptor, the opioid can no longer suppress breathing, and the person typically begins breathing normally again. This is also why the effect is temporary: once naloxone wears off, the opioid can reattach to those receptors if it’s still circulating in the bloodstream.
When Naloxone Is Needed
Recognizing an opioid overdose quickly is what makes naloxone effective. The three hallmark signs are slow, shallow, or irregular breathing; tiny, pinpoint pupils; and unconsciousness or total unresponsiveness. A person may also have blue or grayish lips and fingertips, make gurgling or choking sounds, or have a limp body. If someone shows these signs after known or suspected opioid use, naloxone should be given immediately.
One important safety point: naloxone will not harm someone who hasn’t taken opioids. If you’re unsure whether an overdose involves opioids, it’s still safe to administer it. It simply won’t have any effect on overdoses caused by alcohol, stimulants, or benzodiazepines alone. There is no downside to giving it “just in case.”
How It’s Given
The most widely available form is the 4 mg nasal spray. You place the nozzle into one nostril and press the plunger once. No assembly, no measuring. Each device delivers a single dose. If the person doesn’t start breathing normally within 2 to 3 minutes, you give a second spray using a new device in the other nostril. You can keep repeating every 2 to 3 minutes with a fresh spray until the person responds or emergency help arrives.
Injectable forms also exist and are used by paramedics and in hospitals. Injected into a vein, naloxone works within 1 to 2 minutes. Given as a muscle injection, it takes closer to 2 to 5 minutes. The nasal spray has a similar timeline to the intramuscular route. Regardless of the form used, emergency services should always be called. Naloxone buys time, but it doesn’t replace medical care.
How Long the Effects Last
Naloxone’s protective window is relatively short. After an intravenous dose, its effects last roughly 45 minutes, and intramuscular or nasal doses can last somewhat longer. Many opioids, particularly long-acting ones and fentanyl, remain active in the body well beyond that window. This means a person who appears to recover can slide back into overdose once the naloxone wears off. This “rebound” is why repeated doses may be necessary and why staying with the person and waiting for medical help is critical.
What Withdrawal Feels Like After Naloxone
Because naloxone strips opioids off brain receptors so abruptly, it can trigger what’s called precipitated withdrawal in someone who is physically dependent on opioids. This isn’t a gentle comedown. Within minutes, the person may experience watery eyes, a runny nose, intense sweating, hot flashes, yawning, and visibly dilated pupils. They may also feel nauseous, irritable, or agitated.
These symptoms are deeply uncomfortable but not life-threatening. Some people wake up confused or angry after receiving naloxone because they’ve been thrown into sudden withdrawal. This is a normal reaction, not a reason to avoid giving it. The alternative, letting an overdose continue untreated, is fatal.
Where to Get It
The FDA approved the 4 mg naloxone nasal spray for over-the-counter sale in March 2023, making it available without a prescription at drug stores, grocery stores, gas stations, and online retailers. Other formulations and dosages still require a prescription. Many community organizations, harm reduction programs, and local health departments also distribute naloxone for free, often alongside brief training on how to use it.
Cost varies depending on the retailer and whether insurance is involved. Some states have standing orders that allow pharmacists to dispense naloxone even for prescription-only forms without a personal prescription from a doctor.
Naloxone During Pregnancy and Breastfeeding
Studies have not shown an increased chance of birth defects from naloxone exposure. However, because it reverses opioid effects so suddenly, it can trigger withdrawal in a pregnant person who is physically dependent on opioids. It’s not fully known how that withdrawal affects pregnancy, though one study linked naloxone use to a possible increase in preterm delivery and low birth weight. For newborns, there is a chance of neonatal abstinence syndrome, a set of withdrawal symptoms including irritability, poor feeding, sneezing, and excessive sleepiness that typically appear about two days after birth.
In a life-threatening overdose during pregnancy, naloxone is still used because the immediate risk of death outweighs potential complications. Naloxone passes into breast milk in small amounts, but very little is absorbed by the infant’s digestive system.
Public Health Impact
Widespread naloxone distribution has become a cornerstone of the response to the opioid crisis. Modeling research from the University of Minnesota found that increasing the supply of naloxone in communities could reduce overdose deaths by about 6%, while strategies focused on getting naloxone to people most likely to witness an overdose could achieve closer to a 9% reduction. The most striking finding: combining naloxone distribution with efforts to reduce solitary drug use (since someone must be present to administer it) could cut opioid overdose deaths by up to 37%.
That last number highlights naloxone’s biggest limitation. It only works if someone is there to give it. A person who overdoses alone, no matter how many doses of naloxone are in the medicine cabinet, won’t benefit. Programs that address isolation alongside access are showing the greatest potential to save lives.